| HOME >> BIOLOGY >> TECHNOLOGY |
Gain on sale of subsidiary - - 78,352 -
Net (loss) income from discontinued
operations - (1,179) 75,361 (2,675)
Net (loss) income ($2,571) ($15,796) $25,398 ($59,839)
Basic and diluted net loss per
share from continuing operations ($0.05) ($0.27) ($0.89) ($1.04)
Basic and diluted net (loss) income
per share from discontinued
operations - (0.02) 1.35 (0.05)
Basic and diluted net (loss) income
per share ($0.05) ($0.29) $0.45 ($1.09)
Weighted average number of shares
used in computing basic and
diluted net (loss) income per
share 56,279 54,784 55,853 54,896
SELECTED BALANCE SHEET INFORMATION
December 31, December 31,
2007 2006
(unaudited)
Cash and investments $100,444 $164,393
Restricted cash 14,533 -
Total cash and investments and
restricted cash 114,977 164,393
Working capital 107,844 95,985
Total assets 119,282 227,294
4% Convertible subordinated notes due 2011 69,890 110,000
6% Convertible subordinated debentures
due 2007 - 66,228
Total convertible subordinated
notes and debentures 69,890 176,228
<| SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved |